With only three bispecific antibodies on the market, potential for the technology remains largely untapped. Johnson & Johnson’s Janssen Biotech Inc. is trying to change that. In a new deal with U.K.-based F-star Therapeutics Inc., it’s seeking develop a new generation of bispecifics for undisclosed targets.